American Heart Association

November 13, 2022

Our editorial team has compiled a list of the top data and news from the American Heart Association 2022 Scientific Sessions, with a focus on heart failure, hypertension, and lipid management.

November 09, 2022

Viet Le, PA-C, discusses a study from Intermountain Healthcare examining clinical predictors of medical therapy-induced LVEF improvement in patients with heart failure with reduced ejection fraction in real-world settings.

November 08, 2022

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

November 07, 2022

Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.

November 07, 2022

Data from a pair of presentations at AHA 2022 Scientific Sessions provide clinicians with insight into the effects of surgical vs endovascular procedures for improving prognosis and reducing amputation in patients with peripheral artery disease.

November 07, 2022

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

November 07, 2022

Results of the STRONG-HF trial provide the first evidence from a randomized clinical trial that rapid, in-hospital initiation of guideline-directed medical therapy in heart failure can improve patient outcomes.

November 06, 2022

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.

November 06, 2022

The late-breaking findings suggest the potential prognostic benefit of highly purified EPA in patients with chronic CAD with a low EPA/AA ratio.

November 06, 2022

Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.